“JAK inhibitors appear to be quite versatile molecules when it comes to treating inflammatory skin diseases, which is exciting. The fact that we could fill a symposium with presentations discussing new observations about treatment with these drugs within the past year is very telling,” notes symposium moderator
The following abstracts are scheduled to be presented at the symposium:
- Tofacitinib for recalcitrant cutaneous dermatomyositis. Abeer Alsarheed,
Cambridge, MA.Abstract #503
- CXCL9 drives morphea pathogenesis in mice. Druhmil Patel,
Worcester, MA.Abstract #102
- Photosensitivity and heightened type I IFN responses in cutaneous lupus are driven by elevated interferon kappa.
Mrinal Sarkar, Ann Arbor, MI.Abstract #072
- Tofacitinib leads to increased infections by downregulation of antiviral immune defense. Heike C. Hawerkamp,
Dusseldorf, Germany. Abstract #1056
- RAGE mediates UVB-induced persistent DNA Damage Response (DDR) and resistance to apoptosis in human melanocytes.
Lynn A. Cornelius, St. Louis, MO.Abstract #1215
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia. Jindapa Thummakriengkrai,
Thammasat University, Thailand. Abstract #1311
- Efficacy of oral tofacitinib in the treatment of lichen planopilaris.
Brigitte Sallee, MD, New York, NY. Abstract #491
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ clinical development of its JAK inhibitor drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended
Senior Vice President
Corporate Strategy/Investor Relations
Source: Aclaris Therapeutics, Inc.